Top Cefixime Brands You Should Know About

Cefixime, an antibiotic used to treat a variety of bacterial infections, is available under several trusted brand names worldwide. When choosing the best brand of cefixime, it's essential to consider options that are known for their quality and effectiveness. Some well-established brands include Suprax, Lupin's Cefixime, and Alkem's Taxim-O. Each of these brands offers cefixime in different forms and dosages to suit varying medical needs. To learn more about these brands and see a comprehensive list, please continue reading below.

Illustration of cefixime

Best brands of cefixime in 2025

Lupin

Lupin Pharmaceuticals Inc. is a leading producer of cefixime, with its Suprax brand being a top-selling pediatric antibiotic in the US generics market. Lupin's cefixime formulations have demonstrated bioequivalence to the reference listed drug (RLD), with 90% confidence limits for AUC and Cmax within 80% to 125% under fasting conditions. The company's cefixime products show high accuracy and precision, with accuracy ranging from 96.03% to 101.98% and precision (%CV) ranging from 1.91% to 6.23%. Lupin's US subsidiary is a significant player, with a $891 million enterprise value and a market share of 5.3% by prescriptions, making it the 5th largest and fastest-growing generics player in the US. The company's strong presence in the pharmaceutical market is further highlighted by its leadership in 28 out of 77 products in the US generics market.

Cipla

Cipla Limited is a leading producer of cefixime, contributing significantly to the global market. The company's cefixime capsules dominate a substantial share, with the 400 mg dosage segment accounting for 65% of the market in 2020. Cipla's presence in the retail pharmacy segment is also prominent, holding a 60% market share in 2020. The Asia-Pacific region, where Cipla operates, is expected to grow at a CAGR of 7.5% from 2024 to 2033, driven by a large patient population and improving healthcare infrastructure. Cipla's commitment to providing effective and affordable antibiotic treatments has been a key factor in the market's growth. For further insights into the cefixime capsules market, visit the linked resource.

Mankind Pharma

Mankind Pharma is a leading producer of cefixime, with its brand Mahacef ranking among the top in the anti-infective segment. In FY22, Mahacef held a market share of 2.7% in the cefixime market, with sales of Rs 756 million. The company's cefixime formulations, including Mahacef and Cefakind, are widely prescribed, contributing to Mankind Pharma's strong presence in the Indian pharmaceutical market. Mankind Pharma's domestic sales grew at a CAGR of 12% from FY20 to MAT December 2022, outpacing the Indian Pharmaceutical Market (IPM). The company's focus on chronic and acute therapies has further solidified its position as one of the top pharma companies in India. For more detailed insights, you can refer to their Mankind Pharma IPO document.

Zydus Cadila

Zydus Cadila is a leading producer of cefixime, known for its high-quality formulations and significant market presence. The company is one of the key players in the cefixime oral suspension market, which was valued at approximately USD 1.2 billion in 2023 and is projected to grow at a CAGR of 8.2% from 2024 to 2033. Zydus Cadila's contribution to the market is notable, especially in regions like Asia-Pacific, where the demand for effective and affordable antibiotic treatments is high. The company's products, including cefixime, are widely prescribed for treating various bacterial infections, reflecting their reliability and efficacy. With a strong focus on research and development, Zydus Cadila continues to expand its market share in the global pharmaceutical industry.

Aurobindo Pharma

Aurobindo Pharma is a leading manufacturer of cefixime, a third-generation cephalosporin antibiotic, known for its efficacy in treating bacterial infections. The company's cefixime products are widely distributed and respected for their quality, with Aurobindo Pharma being one of the major players in the cefixime market, which is projected to grow at a CAGR of 4.9% from 2024 to 2031. Aurobindo Pharma's commitment to research and development ensures that their cefixime formulations meet stringent regulatory standards, with about 50% of the absorbed dose excreted unchanged in the urine within 24 hours. The company's global reach and expanding distribution networks, particularly in emerging economies, have significantly contributed to the market's growth. Aurobindo Pharma's cefixime products are available in various dosages, including 400 mg tablets, which attain peak serum levels in approximately 4 hours.

Sun Pharmaceutical

Sun Pharmaceutical, a leading player in the pharmaceutical industry, is renowned for its high-quality production of cefixime, a third-generation cephalosporin antibiotic. The company has adeptly navigated challenges such as the COVID-19 pandemic, during which there was a significant increase in raw material prices, including a near-80% price hike in some materials, yet managed to maintain its production capacity. Sun Pharma's commitment to domestic manufacturing is highlighted by its involvement in the Production Linked Incentive (PLI) scheme, aimed at reducing dependence on Chinese imports and promoting local production of critical bulk drugs like cefixime. The company's resilience and strategic initiatives have contributed to the growth of the cefixime market, which is projected to reach USD 1,850 million by 2031, growing at a CAGR of 4.9%. Sun Pharma's expertise and market presence make it a trusted name in the production and supply of cefixime.

Alkem Laboratories

Alkem Laboratories is a leading producer of cefixime, demonstrating strong performance in the pharmaceutical industry. In the financial year 2021-22, Alkem reported a 20% year-on-year revenue growth, with a significant contribution from its anti-infective segment, which includes cefixime. The company's domestic business in India saw a 29.9% growth, and its international markets, particularly in Latin America and Europe, showed robust growth of 34.8% and 33% respectively in subsequent years. Alkem has a strong pipeline of ANDA filings, with over 176 ANDAs filed with the US FDA as of March 2024, indicating its commitment to expanding its product portfolio. The company's manufacturing facilities comply with cGMP guidelines, ensuring high-quality production. For more information, visit their official website.

Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a leading producer of cefixime, known for its high-quality pharmaceutical formulations. The company has seen significant growth, with an 18% year-over-year (YoY) growth in Q2FY25 revenues in India, driven by new product launches and increased sales volumes. Dr. Reddy's Laboratories is one of the major players in the cefixime market, which is projected to grow at a CAGR of 4.9% from 2024 to 2031. The company's strong presence in various regions, including North America and the Asia-Pacific, further solidifies its position in the market. Dr. Reddy's commitment to innovation and regulatory compliance ensures the reliability and effectiveness of its cefixime products.

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a leading producer of cefixime, a widely used antibiotic, demonstrating its commitment to quality and compliance. The company has garnered a significant market share for its cefixime formulations, boasting an 18.34% market share for cefixime capsules 200mg as of 2023. Glenmark's manufacturing facilities, including its new plant in Monroe, North Carolina, are designed to meet the highest international standards, such as those set by the US FDA and WHO-GMP. The company's strong R&D investments and regulatory approvals, including 24 ANDAs in 2016, further solidify its position in the generics market. With a global workforce and multiple facilities across four continents, Glenmark ensures consistent high-quality production.

Torrent Pharmaceuticals

Torrent Pharmaceuticals is a leading producer of cefixime, showcasing robust growth with a 15% increase in revenue for the quarter ended June 2023, outpacing the BGx market growth of 11%. The company, ranked 6th in the Indian Pharmaceuticals Market, has a strong presence in over 50 countries and is the largest Indian pharma company in Brazil and Germany. With a significant focus on therapeutic segments including anti-infectives, Torrent Pharma's cefixime contributes to its annual revenue of more than Rs 9,600 crores. The company's R&D investments, employing over 750 scientists, drive innovation and compliance with stringent regulatory standards. Its manufacturing facilities, including 5 USFDA-approved plants, ensure high-quality production. For more details on their offerings, visit Torrent Pharmaceuticals' official website.